Open company graph database — free web & API
Login

Wakimoto Pharmaceutical Co., Ltd.

わかもと製薬株式会社WAKAMOTO PHARMACEUTICAL CO., LTD.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
425
Related companies
12
§01

Basic information

BASIC
Head office
2-2-2 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8330, Japan
Chief executive
Tomoyuki Hirai
Capital
3,395,000,000  (33 100 million)
Employees (non-consolidated)
286 people
Employees (consolidated)
425 people
Start date
1929-04-01
End date
§02

Websites

1 DOMAINS
§03

Business

4
Manufacturing and sale of pharmaceuticalsManufacturing and sale of quasi-drugsManufacturing and sale of medical devicesManufacturing and sale of health foods
§04

Related companies

12 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
株式会社わかもと本舗栄養と育児の会
Group
株式会社栄養と育児の会
Group
アバンビーズ
Customer
アバンビーズ オーラルタブレット
Customer
アレジフェンス
Customer
コーラルε
Customer
フェミフローラ
Customer
フェミフローラ 大豆イソフラボン マカ&ギャバ
Customer
フェミフローラ 葉酸プラス
Customer
フェミフローライン デリケート保湿クリーム
Customer
強力わかもと
Customer
顆粒わかもと
Customer
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

67 EVENTS

April 1929: Established the partnership company "Nutrition and Childcare Association" at Shiba Park, Shiba-ku, Tokyo, and launched "Wakimoto".Sources

Established a joint‑stock company "Nutrition and Childcare Association" at Daimon, Shiba Park, Shiba‑ku, Tokyo City, and launched "Wakamoto".Sources

January 1933: Established "Nutrition and Childcare Association Co., Ltd." in Shiba Park, Shiba-ku, Tokyo, and began manufacturing and selling the digestive, intestinal, and nutritional agent "Wakimoto".Sources

Established "Corporation Nutrition and Childcare Association" in Shiba Park, Shiba‑ku, Tokyo City, and began manufacturing and selling the digestive, intestinal health, and nutrition agent "Wakamoto".Sources

December 1935: Renamed the company to "Wakimoto Honpo Nutrition and Childcare Association Co., Ltd.".Sources

Renamed the company name to "Corporation Wakamoto Honpo Nutrition and Childcare Association".Sources

July 1943: Renamed the company to its current name "Wakimoto Pharmaceutical Co., Ltd.".Sources

Renamed the company name to the current "Wakamoto Pharmaceutical Co., Ltd.".Sources

May 1949: Listed on the Tokyo Stock Exchange.Sources

Listed on the Tokyo Stock ExchangeSources

Since its founding, our company has developed products that contribute to the health maintenance of the public by utilizing lactic acid bacteria technology. In 1955, we incorporated lactic acid bacteria into "Wakamoto".Sources

Added lactic acid bacteria to 'Wakamoto'.Sources

January 1962: Released "Kouryoku Wakimoto", an enhanced product featuring digestive enzymes, active lactic acid bacteria, vitamins B1 and B2, and nicotinamide.Sources

Released 'Strong Wakamoto' with enhanced digestive enzymes, active lactic acid bacteria, vitamins B1, B2, and nicotinamideSources

June 1968: Established the Sagami-Oi factory and research facilities in Oi-machi, Sagamihara, Kanagawa Prefecture.Sources

Established the Sagami Oi factory and research facilities in Oi-machi, Sagamihara, Kanagawa PrefectureSources

In 1970, we began selling the antibiotic and chemotherapy‑resistant lactic acid bacteria formulation "Rebenin".Sources

Started sales of antibiotic and chemotherapy-resistant lactic acid bacteria formulation 'Rebenin'.Sources

August 1983: Launched the medicated toothpaste "Coral" (now Coral ε).Sources

Released medicinal toothpaste 'Coral' (now Coral ε)Sources

September 1983: Listed on the First Section of the Tokyo Stock Exchange.Sources

Listed on the First Section of the Tokyo Stock ExchangeSources

January 1989: Issued the first series of secured convertible bonds with a total face value of 4 billion yen.Sources

Issued the first series of asset-backed convertible bonds with a total face value of 4 billion yenSources

May 1989: Released the water-soluble non-steroidal anti-inflammatory eye drop "Dicloid Eye Drops 0.1%".Sources

Released aqueous non-steroidal anti-inflammatory eye drop 'Dicloid 0.1%'Sources

In 1995, we sold "Wakamoto Intestinal Health Medicine", the first over‑the‑counter product to incorporate two strains of Bifidobacteria.Sources

Sold 'Wakamoto Intestinal Health Medicine', the first over-the-counter drug to combine two Bifidobacterium strains.Sources

December 1995: Released the lactic acid bacteria intestinal regulator "Wakimoto Intestinal Medicine".Sources

Released lactic acid bacteria intestinal regulator 'Wakamojo Seichouyaku'Sources

November 1999: Released "Rizmon TG Eye Drops", the world's first heat-responsive gel technology eye drop for glaucoma and ocular hypertension.Sources

Released the world's first thermoresponsive gel technology eye drop, glaucoma and ocular hypertension treatment 'Rizmon TG Eye Drop'Sources

November 2000: Released "Zepelin Eye Drops 0.1%" for allergic conjunctivitis.Sources

Released allergy conjunctivitis treatment 'Zepelin 0.1% eye drop'Sources

August 2002: Obtained ISO 14001 certification for the environmental management system at the Sagami-Oi factory.Sources

Obtained ISO 14001 certification for the Sagami Oi factory environmental management systemSources

In 2005, we sold "AvanBees", the first Japanese medicated toothpaste containing live lactic acid bacteria.Sources

Sold 'Avanbees', the first Japanese medicinal toothpaste containing live lactic acid bacteria.Sources

November 2005: Released the medicated toothpaste "Avanbees".Sources

Released medicinal toothpaste 'Avanbees'Sources

July 2007: Release of the glaucoma and ocular hypertension treatment drug "Nipradilol eye drops 0.25% 'Wakamoto'" (first product to adopt preservative‑free NP container).Sources

Released glaucoma and ocular hypertension treatment 'Nipradilol 0.25% Wakamojo' (first product to use preservative-free NP container)Sources

December 2010: Release of ophthalmic surgery adjunct "MakuAid intravitreal injection 40mg" (now ophthalmic surgery adjunct and ophthalmic corticosteroid "MakuAid eye injection 40mg").Sources

Released ophthalmic surgery adjunct 'MakuAid intravitreal injection 40mg' (now ophthalmic surgery adjunct and ophthalmic adrenal cortex hormone 'MakuAid eye injection 40mg')Sources

April 2014: Moved headquarters to 2‑2‑2 Nihonbashi‑Honcho, Chuo‑ku, Tokyo.Sources

Moved headquarters to 2-2-2 Nihonbashi Motomachi, Chuo-ku, TokyoSources

October 2015: Release of supplement "OptiAid DE".Sources

Released supplement 'OptiAid DE'Sources

In 2017, we sold "AvanBees Oral Tablet", a processed food with a new lactic acid bacteria formulation suitable for oral care.Sources

Sold 'Avanbees Oral Tablet', a processed food with new lactic acid bacteria suitable for oral care.Sources

April 2017: Release of lactic acid bacteria‑containing processed food "AvanBees Oral Tablet".Sources

Released lactic acid bacteria-containing processed food 'Avanbees Oral Tablet'Sources

Developed products applying proprietary fermentation and cultivation technologies centered on 'Strong Wakamoto'.Sources

October 2018: Release of allergy‑specific ophthalmic drug "Allergifence".Sources

Released allergy-specific ophthalmic drug 'Allegifense'Sources

August 2019: Release of functional food "OptiAid ML MACULAR".Sources

Released functional food 'OptiAid ML MACULAR'Sources

April 2022: Transitioned to the Tokyo Stock Exchange's new market category "Standard Market".Sources

Transitioned to the Standard Market of the Tokyo Stock ExchangeSources

Since 2023, we have begun selling femcare products (supplements, protein, etc.) that can be easily incorporated into daily life and provide counseling for women's concerns, thereby developing new businesses.Sources

Launched femcare products (supplements, protein, etc.) that can be easily incorporated into daily life and provide women's counseling, creating a new business.Sources

April 2023: Release of femtech brand "Femflora".Sources

Release of femtech brand 'Femflora'.Sources

June 2025: Release of multifocal intraocular lens "Aciravitrova Pro (Non‑toric)" featuring sinusoidal diffraction structure.Sources

Launch of multifocal intraocular lens 'Aciravitro Nova Pro (Non-Topical)' with sinusoidal diffraction structure.Sources

Conference presentation.Sources

Assumed presidency.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information1010001035010
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
わかもと製薬株式会社
Trade name (kana)
ワカモトセイヤク
Name in English
Corporation type
301
Address
〒103-0023 東京都中央区日本橋本町2丁目2番2号
Postal code
1030023
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-04-10
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
1271608
METI gBizINFO1010001035010
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
1010001035010
Trade name
わかもと製薬株式会社
Trade name (kana)
ワカモトセイヤク
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都中央区日本橋本町2丁目2番2号
Postal code
1030023
Prefecture
東京都
Prefecture code
13
City or district
中央区
City code
102
Street address
日本橋本町2丁目2番2号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役社長  平井 友行
Capital
3395887000
Employees
303
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-04-10
Key information
1010001035010
§09

Sources & updates

SOURCES
↑